Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4439-4444

  Kato, Hiroyuki ^a   Miyazaki, Tatsuya ^a   Nakajima, Masanobu ^a   Takita, Junko ^a   Kimura, Hitoshi ^a   Faried, Ahmad ^a   Sohda, Makoto ^a   Fukai, Yasuyuki ^a   Masuda, Norihiro ^a   Fukuchi, Minoru ^a   Manda, Ryokuhei ^a   Ojima, Hitoshi ^a   Tsukada, Katsuhiko ^a   Kuwano, Hiroyuki ^a   Oriuchi, Noboru ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

18 F Fluorodeoxyglucose (FDG); Bone scintigraphy; Bony metastasis; Esophageal carcinoma; Positron emission tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CLAVICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ESOPHAGUS CARCINOMA; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; OSTEOLYSIS; PELVIC GIRDLE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RIB; SCAPULA; SPINE METASTASIS; STERNUM; TUMOR RECURRENCE; VALIDATION PROCESS; WHOLE BODY TOMOGRAPHY;

ADULT; AGED; BONE NEOPLASMS; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE;

EID: 28444476152     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bar-Shalom R, Valdivia AY and Blaufox MD: PET imaging in oncology. Semin Nucl Med 30: 150-185, 2000.
2. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U et al: F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192: 79-86, 1994.
3. Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH et al: Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 36: 788-793, 1995.
4. Ahuja V, Coleman RE, Herndon J and Patz EF: The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83: 918-924, 1998.
5. Coleman RE: PET in lung cancer. J Nucl Med 40: 814-820, 1999.
6. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, Siegel BA and Cooper JD: Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 64: 770-776, 1997.
7. Luketich JD, Schauer PR, Meltzer CC, Landreneau RJ, Urso GK, Townsend DW, Ferson PF, Keenan RJ and Belani CP: Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 64: 765-769, 1997.
8. Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA and Cooper JD: Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168: 417-424, 1997.
9. Kole AC, Plukker JT, Nieweg OE and Vaalburg W: Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 78: 521-527, 1998.
10. Rankin SC, Taylor H, Cook GJ and Mason R: Computed tomography and positron emission tomography in the preoperative staging of oesophageal carcinoma. Clin Radiol 53: 659-665, 1998.
11. Kobori O, Kirihara Y, Kosaka N and Hara T: Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer 86: 1638-1648, 1999.
12. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD and Larson SM: FDG-PET in esophageal cancer. Incremental value over computed tomography. Clin Positron Imaging 2: 255-260, 1999.
13. McAteer D, Wallis F, Couper G, Norton M, Welch A, Bruce D, Park K, Nicolson M, Gilbert FJ and Sharp P: Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 72: 525-529, 1999.
14. Skehan SJ, Brown AL, Thompson M, Young JE, Coates G and Nahmias C: Imaging features of primary and recurrent esophageal cancer at FDG-PET. Radiographics 20: 713-723, 2000.
15. Flamen P, Lerut A, Van Cutsem E, Cambier JP, Maes A, De Wever W, Peeters M, De Leyn P, Van Raemdonck D and Mortelmans L: The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 120: 1085-1092, 2000.
16. Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR and Schwaiger M: Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233: 300-309, 2001.
17. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M and Fink U: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19: 3058-3065, 2001.
18. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, De Leyn P, Van Raemdonck D, De Wever W, Ectors N, Maes A and Mortelmans L: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13: 361-368, 2002.
19. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, Fukuchi M, Manda R, Tsukada K, Oriuchi N and Endo K: Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184: 279-283, 2002.
20. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsukada K, Oriuchi N, Inoue T and Endo K: Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94: 921-928, 2002.
21. Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R and Kuwano H: Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 94: 1004-1009, 2004.
22. Kato H: Diagnosis and treatment of oesophageal neoplasms. Jpn J Cancer Res 86: 993-1009, 1995.
23. Rybak LD and Rosenthal DI: Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med 45: 53-64, 2001.
24. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B and Rigo P: Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25: 1244-1247, 1998.
25. Gayed I, Vu T, Johnson M, Macapinlac H and Podoloff D: Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 5: 26-31, 2003.
26. Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, Nasu S, Suzuki Y, Yasuda S and Shohtsu A: Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with Tc99m-MDP bone scintigraphy. Nucl Med Commun 22: 875-879, 2001.
27. Cook GJ, Houston S, Rubens R, Maisey MN and Fogelman I: Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16: 3375-3379, 1998.
28. Shreve PD, Grossman HB, Gross MD and Wahl RL: Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199: 751-756, 1996.
29. Inoue T, Oriuchi N, Kunio M et al: Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun 20: 849-857, 1999.
30. Beck JR: Likelihood ratios. Another enhancement of sensitivity and specificity. Arch Pathol Lab Med 110: 685-686, 1986.
31. Dwyer AJ: Matchmaking and McNemar in the comparison of diagnostic modalities. Radiology 178: 328-330, 1991.
32. Malhotra P and Berman CG: Evaluation of bone metastases in lung cancer. Improved sensitivity and specificity of PET over bone scanning. Cancer Control 9: 259-260, 2002.
33. Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jurgens H, Schober O and Rummeny EJ: Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 177: 229-236, 2001.
34. Kao CH, Hsieh JF, Tsai SC, Ho YJ and Yen RF: Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 20: 2189-2192, 2000.
35. Nakamoto Y, Osman M and Wahl RL: Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin Nucl Med 28: 302-307, 2003.
36. Peterson JJ, Kransdorf MJ and O'Connor MI: Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop 415: S120-128, 2003.
37. Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P and Lind P: F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 58: 250-256, 2003.
38. Cheran SK, Herndon JE 2nd and Patz EF Jr: Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 44: 317-325, 2004.
39. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, Yamaura G, Takahashi H, Fukuda H and Kanamaru R: Evaluation of 18F-FDG PET in patients with a metastatic or recurrent gastric cancer. J Nucl Med 44: 690-699, 2003.
40. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC and Lee CC: Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 128: 325-328, 2002.
41. Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, Neumaier B, Trager H, Nussle K and Reske SN: Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 40: 1623-1629, 1999.